Board of directors
CHRIS WOOD is Chairman of the Thirty Group Board, Chief Medical Officer, and also Director of each of Thirty’s subsidiary companies.
Chris founded the business and led the Group’s research and development program that is at the heart of the Group’s core technology. Chris has more than 20 years of experience in the biotechnology sector, having founded, managed and successfully exited four companies including Bioenvision and Medirace. Prior to this Chris was a consultant surgeon at the Royal Postgraduate Medical School. Chris is Executive Chairman of NuCana plc (NASDAQ: NCNA), Medannex Limited and Oncobiopharm Limited, and a Non-Executive Director of MiNA Therapeutics.
JUSTIN BARNES is a Group Executive Director and Board member of the Thirty Group, and also Director of each of Thirty’s subsidiary companies. Justin co-heads the Leadership team.
Justin was instrumental in the development of Thirty’s core technology and brings to the Group a successful 30-year track record in the Healthcare industry. During this time Justin has built and sold several international companies, each with global research, development, manufacturing and sales organisations. Justin is also a Non-Executive Director of Rayner Surgical Group, and a partner in a healthcare VC firm. Prior to his business career, Justin was a soldier in the British Army.
SYD HANNA is a Group Executive Director and Board member of the Thirty Group, and also Director of each of Thirty’s subsidiary companies. Syd co-heads the Leadership team.
Syd joined Edixomed as a Board Director in 2012 and has overseen the business strategy, financing and execution of the research program. Syd has extensive experience building businesses with private and institutional investor backing across the drug discovery, medical device and financial services sectors. Syd supports several early stage biopharmaceutical companies and is a Chartered Global Management Accountant.
KEITH LIPMAN is a Group Executive Director and Board member of the Thirty Group, and also Director of each of Thirty’s subsidiary companies.
Keith chairs the Scientific Advisory Committee. Keith is the lead private investor in the business since 2012. He is an investor in, and advisor to, companies principally in the data and scientific fields. Keith earned his PhD in Astrophysics from Cambridge University in 1992. He was a founder of a group of companies created to use scientific research to design algorithms to predict the future movements of financial securities. This proprietary firm was one of the largest trading firms in the financial markets.
ISAAC CHENG is a Non-Executive Director on the Board of Thirty Group.
Isaac is currently an investment advisor at Morningside Technology Advisory LLC, a venture capital firm he joined in 2006, and is also a Director of Cognoa, Inc., a digital health company, and several biopharmaceutical or biotechnology companies, including: Liquidia Technologies, Inc., Artugen Therapeutics Limited, Amylyx Pharmaceuticals Inc. and K-Gen, Inc.
HUGH GRIFFITH is a Non-Executive Director on the Board of Thirty Group.
Hugh serves as Chief Executive Officer and as a member of Board of Directors of NuCana plc (NASDAQ: NCNA) a clinical stage biopharmaceutical company. Hugh also serves as a Non-Executive Director of MedAnnex Limited and is on the advisory board of the Scottish Lifesciences Association.
30 TECHNOLOGY is developing and defining new models of care to treat many serious medical conditions by enhancing the body’s healing and defence mechanisms.
30 TECHNOLOGY Therapeutic Nitric Oxide